Opus Genetics IRD Increase in accrued expenses and other liabilities
Increase in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's increase in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's increase in accrued expenses and other liabilities?
- Opus Genetics (IRD) reported increase in accrued expenses and other liabilities of $432K in Q1 2026.
- How has Opus Genetics's increase in accrued expenses and other liabilities changed year-over-year?
- Opus Genetics's increase in accrued expenses and other liabilities increased by 58.8% year-over-year, from $272K to $432K.
- What does increase in accrued expenses and other liabilities mean?
- Reflects the net change in short-term obligations for expenses incurred but not yet invoiced or paid, such as accrued compensation or professional fees. Monitoring this helps investors understand the timing of cash outflows related to operational commitments.